1. Home
  2. Press Releases

Press Releases

BioFactura announces initiation of Phase I study of BFI-751, a Stelara® (ustekinumab) biosimilar

Frederick, Maryland, May 25, 2021: BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first … Continue reading

May 25, 2021 Press Releases

BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic

Frederick, Maryland, February 19, 2021:  BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at … Continue reading

February 19, 2021 Press Releases

BioFactura Granted New US AND European Patent for Its StableFast Biomanfacturing Platform

Frederick, Maryland, September 24, 2020: BioFactura, Inc. was issued a new patent in the U.S. and also granted patent coverage in the EU for novel technologies that improve the productivity of its proprietary StableFastTM Biomanufacturing Platform.  The new Multiplex Selection components of the platform allow for concurrent selection strategies to be applied during stable cell … Continue reading

September 24, 2020 Press Releases

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic

Frederick, Maryland, July 27, 2020: BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD).  The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based … Continue reading

July 27, 2020 Press Releases

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Frederick, Maryland, September 26, 2019:  BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox.  This product has the potential to fulfill an … Continue reading

September 26, 2019 Press Releases

University of Vermont Health Network Ventures and Wilson Sonsini Goodrich & Rosati Invest in BioFactura

Frederick, Maryland, April 29, 2019:  The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. “With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as … Continue reading

April 29, 2019 Press Releases